The aim of this study was to compare the performance of serological versus molecular typing methods to detect capsular polysaccharide (CP) and surface-associated polysaccharide antigen 336 phenotypes of Staphylococcus aureus isolates. Molecular typing of CP types 1, 5 and 8 was carried out using PCR, whereas serological typing of CP1, 2, 5, 8 and antigen 336 was carried out by slide agglutination using specific antisera. By genotyping, 14/31 strains were CP8 positive, 12/31 strains were CP5 and the remaining 6/31 isolates were non-typable (NT). One isolate was positive for both CP5 and CP8 by PCR, but was confirmed as CP8 type serologically. Detection of CP2 and type 336 by PCR was not possible because specific primers were either not available or non-specific. Using serotyping, 14/31 strains were CP8 positive, 11/31 CP5 positive and 2/31 positive for antigen 336. The remaining four S. aureus isolates were serologically NT. However, three of four NT and two 336-positive S. aureus isolates were encapsulated as determined by light microscopy after capsular staining. This discovery was surprising and warrants further investigations on the identification and characterization of additional capsular phenotypes prevalent among S. aureus clinical isolates. It was concluded that serological typing was a better method than molecular typing for use in epidemiological investigations based upon the distribution of surface-associated polysaccharide antigens-based phenotypes.
INTRODUCTION
Staphylococcus aureus is an important human pathogen causing a broad range of infectious diseases facilitated by its ability to asymptomatically colonize healthy individuals (Daum & Spellberg, 2012; Foster, 2004) . The most common conditions associated with this pathogen include wound infections, boils, carbuncles and impetigo, which typically follow abrasions of the skin or mucosal surfaces. The organism can further invade the body or be introduced through medical devices, resulting in systematic infections ranging from osteomyelitis and pneumonia to septicaemia, meningitis and endocarditis (O'Riordan & Lee, 2004; Tzianabos et al., 2001) . S. aureus is also a common pathogen of immunocompromised patients and a leading nosocomial pathogen in nursing homes, and neonatal care and intensive care units (Ohlsen & Lorenz, 2010) .
S. aureus produces several virulence factors, among which the capsular polysaccharides (CPs), which are anti-phagocytic (Sutter et al., 2011) , have been widely used as vaccine targets (O'Riordan & Lee, 2004; Robbins et al., 2004) . Initial studies, using agglutination tests, reported the existence of 11 CP types based on serological specificity (Sompolinsky et al., 1985; Karakawa et al., 1988) . However, studies carried out later reported the existence of only four capsular types, 1, 2, 5 and 8, with the remaining types representing mutated forms of one or more of the CP types (O'Riordan & Lee, 2004 , Fattom et al., 1998 . Many previous studies reported the majority of human S. aureus strains (70-80 %) to possess either CP5 and/or CP8 (Skurnik et al., 2010; Roghmann et al., 2005; Verdier et al., 2007) , which underpinned the rationale of targeting these two predominant types for the development of conjugate vaccines against infections caused by S. aureus. S. aureus strains that harboured the capsule locus for CP5 or CP8, but were non-typable (NT) by serological methods for CP1, 2, 5 and 8, were labelled as serotype 336, a surface-associated polysaccharide antigen that is a variant of S. aureus cell wall teichoic acid (Sutter et al., 2011) . The aim of this study was to compare the performance of serological versus molecular typing methods in determining the distribution of different surface-associated capsular and somatic polysaccharide 336 phenotypes of S. aureus isolated from Western Australians.
METHODS
Collection of isolates. A total of 31 S. aureus isolates were used in this investigation. A total of 19 of these isolates were obtained from Royal Perth Hospital and Queen Elizabeth II Hospital in Perth, Western Australia, and 12 isolates were collected from undergraduate laboratory medicine students in the School of Biomedical Sciences, Curtin University, Perth, Western Australia (Human Ethics approval no. SoBS 04/11). Positive controls used in this investigation were S. aureus strain M (CP1), Smith Diffuse (CP2), strain Newman (CP5), USA 400 (CP8), LAC USA 300 (CP negative) and an antigen 336-positive American Type Culture Collection (ATCC) S. aureus strain, 55804.
DNA extraction. Prior to use, the strains were freshly cultured in nutrient broth (PathWest media) with a cryobead, followed by incubation overnight in a shaking incubator at 37 uC. DNA was extracted using a commercial kit (MO-Bio; GeneWorks) and stored at 220 uC. All extracts were thawed on ice prior to genotyping using PCR.
Genotyping of CP types. The PCR primers (GeneWorks) used in this study are shown in Table 1 . PCR parameters for cap1 and cap2 were as follows: 94 uC for 5 min (initial denaturation); then 25 cycles of 94 uC for 30 s (denaturation), T m for 30 s (annealing) and 72 uC for 60 s (extension); and 72 uC for 5 min (final extension). PCR parameters for cap5 and cap8 were the same as described previously (Babra et al., 2014) .
PCR products were separated in a 1.5 % agarose gel in 16TAE buffer and the gel was stained with 8 ml Midori Green l 21 (Nippon Genetics). The positive controls used for the PCR were strain M (CP1), Smith Diffuse (CP2), strain Newman (CP5) and USA 400 (CP8), and LAC USA 300 was used for the negative control.
CP serotyping. Serotyping was carried out using an agglutination test as described elsewhere (Verdier et al., 2007) . CP-specific antisera were raised in specific pathogen-free Quackenbush mice, against CP1, CP2, CP5, CP8 and antigen 336 according to the protocol of J. GogoiTiwari and others (unpublished). Briefly, mice were immunized with S. aureus strains M (CP1), Smith Diffuse (CP2), Newman (CP5), USA MW2 (CP8), USA LAC 300 (CP negative) and ATCC 55804 (336) using the following immunization schedule. The first three doses were administered at days 0, 7 and 14. Each dose (0.2 ml per mouse, subcutaneous) consisted of formalin-killed S. aureus without an adjuvant (5610 7 , 1610 8 and 5610 8 c.f.u. at days 0, 7 and 14, respectively). The fourth and fifth doses contained 1610 9 and 5610 9 c.f.u., respectively, mixed equally with the Imject Alum adjuvant (Thermo Scientific). Non-specific reactivity of the typing sera was eliminated by cross-absorption with appropriate S. aureus cells of different serotypes, including the accredited antigen 336 strain (ATCC 55804).
Microscopic detection of capsules. The capsules were stained using a modified Maneval's method (Maneval, 1941; Engelkirk & Duben-Engelkirk, 2008) . Briefly, the modified method involved scraping of biofilm-associated cells, which were spun down at 6000 r.p.m. for 2 min and the bacterial pellet was washed once with 16PBS. Cells were then suspended in a solution of 5 % sucrose and centrifuged at 6000 r.p.m. for 2 min. The supernatant was removed and the pellet was suspended once more in 5 % sucrose. Cells were centrifuged at 9000 r.p.m. for 2 min and the supernatant was removed to obtain as much pellet as possible. Cells in the pellet were gently emulsified in a drop of 1 % Congo red on a clean microscope slide and air dried. The slide was then flooded with Muir's mordant (also known as Maneval's stain) and left to stand for 2 min before rinsing gently with tap water. The slide was then blot dried using clean filter paper and viewed using an oil immersion objective (61000 magnification).
RESULTS AND DISCUSSION
A summary of the results obtained using genotyping versus serotyping methods is shown in Table 2 . Both genotyping and serotyping methods revealed that none of the strains were positive for CP1. Serotyping was the only effective method for the detection of CP2-positive S. aureus strains because the designed primers for cap2 were non-specific and cross-reacted with the positive control strains for cap5, cap8 and cap1, producing 731 bp amplicons (data not shown). However, none of the strains were found to be CP2 positive by serology. Genotyping for cap5 identified 12/31 strains (38.7 %) to be positive, while one strain produced amplicons of the respective expected sizes for both cap5 and cap8 (Table 2) . Serologically, however, this strain agglutinated only with anti-CP8 serum. Both the genotyping and serotyping results were in agreement for CP8, where 14/31 (45.16 %) of the isolates were positive. As primers for type 336 were not available, genotyping for antigen 336 could not be carried out at this time. Using PCR, 6/31 (19.35 %) of the isolates were regarded as NT isolates. A total of 2 of the 6 NT strains, or 2/31 (6.45 %) of the total isolates that were NT either by genotyping or by serotyping, were found to be antigen 336 positive by serotyping. Taken together, a total of 4/31 strains or 12.9 % were regarded as being NT. All of the strains were then subjected to capsular staining. The bacterial cell stained red/purple against a dark background with the capsules appearing as unstained white haloes. Strain USA LAC 300 (CP negative) and one of our test isolates, H7, which was positive for CP5 by genotyping (Babra et al., 2014) and serotyping (this study), were used as negative and positive controls, respectively (Figs 1 and 2) . All of the cap8-positive isolates were found to have a capsule, as did all the cap5-positive isolates, including one strain that was positive for both CP5 and CP8 by PCR but was CP8 positive by serology. Quite surprisingly, it was discovered that three of the four NT isolates were also encapsulated when subjected to capsular staining (Fig. 3) .
S. aureus is the cause of multiple disease syndromes in both community and hospital settings. A well-known and established key factor in its virulence is the production of a capsule (Engelkirk & Duben-Engelkirk, 2008) , an important immune evasion molecule of S. aureus (Nanra et al., 2012) . As such it has been used as a target for vaccine development and evaluated as a key component of conjugate vaccines in preclinical models, as well as in human trials (Nanra et al., 2012; Pozzi et al., 2012) .
Our study has shown that capsular phenotypes 5 and 8 were the predominant capsular phenotypes among the Western Australian S. aureus isolates included in this investigation. However, we found that serological typing using slide agglutination was better for determining capsular phenotype than the genotyping method because of the lack of availability of specific primers for detection of CP2 and antigen 336. Serologically, 80.6 % of the total S. aureus isolates were composed of CP8 (45.16 %) and CP5 (35.48 %), confirming previous reports from select other countries (Roghmann et al., 2005; Verdier et al., 2007;  Skurnik et al., 2010) , the remaining isolates being either antigen 336 positive or NT. Sompolinsky et al. (1985) performed capsular typing of S. aureus isolated from human infections for the 11 capsular serotypes by precipitation and agglutination with specific antisera. This research group reported that 63 % of their isolates were type 8, 16 % were type 5, 2 % were type 7 and 0.3 % were type 10, with more than 90 % of total isolates being encapsulated. The remaining 10 % of the encapsulated isolates were not identified as belonging to the 11 known capsular types, in these isolates the capsule may represent a prototype capsule that is different from the accepted 11 serotypes (Sompolinsky et al., 1985) . This is in contrast to a previous report that the lack of expression of a capsule by NT strains was due to random point mutations in the CP5A promoter or replacement by the insertion sequence IS257 (Cocchiaro et al., 2006) . Our study demonstrated the existence of more serotypes than just the four capsular types (CP1, 2, 5, 8) and also raises a question on the validity of the antigen 336 as a somatic non-capsular antigen.
Given that most vaccines have employed surface-associated polysaccharide antigens, particularly CP5 and CP8, conjugated with one or more potential protein adhesins such as alpha toxin, ClfB and IsdB (Pozzi et al., 2012) , coupled with the fact that no protection is expected to be imparted against infections caused by NT S. aureus, it is important to gain knowledge on the nature of the antigens unique to NT isolates, including new capsular antigens/phenotypes, for the formulation of an improved vaccine against S. aureus. Our study has highlighted the potential importance of determining the prevalence of not only the major capsular serotypes, CP5 and CP8, of S. aureus, but also other antigens particularly antigen 336. The fact that 75 % of the NT S. aureus strains and the antigen 336-positive strain were also found to be encapsulated, even by light microscopy, warrants further investigations on the identification of additional capsular types present among the NT isolates for complete epidemiological investigations and formulation of appropriate conjugate vaccines. . NT CP isolate of S. aureus (CP negative by genotyping and serotyping) displays a capsule using modified Maneval's capsule staining method (¾1000 magnification).
